JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.on behalf of the balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
2.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.on behalf of the balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrol Dial Transplant2012; [Epub ahead of print].
3.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.Y.The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Perit Dial Int2012; 32: 497–506.
4.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain.Kidney Int1998; 53: 1061–7.
5.
HoffC.M.In vitro biocompatibility performance of Physioneal.Kidney Int2003; 88: S57–74.
6.
TranæusA.A long-term study of a bicarbonate/lactate– based peritoneal dialysis solution—clinical benefits. The Bicarbonate/Lactate Study Group.Perit Dial Int2000; 20: 516–23.
7.
FanS.L., PileT., PunzalanS., RafteryM.J., YaqoobM.M.Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.Kidney Int2008; 73: 200–6.
8.
SrivastavaS., HildebrandS., FanS.L.Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.Kidney Int2011; 80: 986–91.
9.
PajekJ., KvederR., BrenA., GucekA., BucarM., SkoberneA.Short-term effects of bicarbonate/lactate–buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.Nephrol Dial Transplant2009; 24: 1617–25.
10.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
11.
SzetoC.C., ChowK.M., LamC.W., LeungC.B., KwanB.C., ChungK.Y.Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—a 1-year randomized control trial.Nephrol Dial Transplant2007; 22: 552–9.
12.
ChoiH.Y., KimD.K., LeeT.H., MoonS.J., HanS.H., LeeJ.E.The clinical usefulness of peritoneal dialysis fluids with neutral pH and low glucose degradation product concentration: an open randomized prospective trial.Perit Dial Int2008; 28: 174–82.
13.
KimS., OhJ., KimS., ChungW., AhnC., KimS.G.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant2009; 24: 2899–908.
14.
WeissL., StegmayrB., MalmstenG., TejdeM., HadimeriH., SiegertC.E.Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution.Perit Dial Int2009; 29: 647–55.
15.
Haag-WeberM., KrämerR., HaakeR., IslamM.S., PrischlF., HaugU.on behalf of the DIUREST Study Group. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
DaviesS.J.Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?Nephrol Dial Transplant2009; 24: 2620–2.
18.
LiP.K., LawM.C., ChowK.M., ChanW.K., SzetoC.C., ChengY.L.Comparison of clinical outcome and ease of handling in two double-bag systems in continuous ambulatory peritoneal dialysis: a prospective, randomized, controlled, multicenter study.Am J Kidney Dis2002; 40: 373–80.
